R
Russell E. Lewis
Researcher at University of Bologna
Publications - 304
Citations - 20160
Russell E. Lewis is an academic researcher from University of Bologna. The author has contributed to research in topics: Aspergillosis & Amphotericin B. The author has an hindex of 73, co-authored 294 publications receiving 16850 citations. Previous affiliations of Russell E. Lewis include University of Crete & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Andrew J. Ullmann,José María Aguado,S. Arikan-Akdagli,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Patricia Muñoz,Paul E. Verweij,Adilia Warris,Florence Ader,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary Ann Barnes,Catherine Beigelman-Aubry,Catherine Beigelman-Aubry,Stijn Blot,Stijn Blot,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt,Jacques Cadranel,Jacques Cadranel,Elio Castagnola,Arunaloke Chakrabarti,Manuel Cuenca-Estrella,George Dimopoulos,George Dimopoulos,Jesús Fortún,Jean-Pierre Gangneux,Jorge Garbino,Werner J. Heinz,Raoul Herbrecht,Claus Peter Heussel,Christopher C. Kibbler,Nikolay Klimko,Bart Jan Kullberg,Christoph Lange,Thomas Lehrnbecher,Jürgen Löffler,Olivier Lortholary,J Maertens,O. Marchetti,Jacques F. Meis,Livio Pagano,Patricia Ribaud,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Maurizio Sanguinetti,Donald C. Sheppard,János Sinkó,Anna Skiada,Maria J G T Vehreschild,Claudio Viscoli,Oliver A. Cornely +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
Oliver A. Cornely,Ana Alastruey-Izquierdo,Dorothee Arenz,Sharon C.-A. Chen,Eric Dannaoui,Bruno Hochhegger,Bruno Hochhegger,Martin Hoenigl,Martin Hoenigl,Henrik Jeldtoft Jensen,Katrien Lagrou,Russell E. Lewis,Sibylle C. Mellinghoff,Mervyn Mer,Zoi D. Pana,Danila Seidel,Donald C. Sheppard,Roger Wahba,Murat Akova,Alexandre Alanio,Abdullah M. S. Al-Hatmi,Sevtap Arikan-Akdagli,Hamid Badali,Ronen Ben-Ami,Alexandro Bonifaz,Stéphane Bretagne,Elio Castagnola,Methee Chayakulkeeree,Arnaldo Lopes Colombo,Dora E. Corzo-Leon,Lubos Drgona,Andreas H. Groll,Jesús Guinea,Jesús Guinea,Claus Peter Heussel,Ashraf S. Ibrahim,Souha S. Kanj,Nikolay Klimko,Michaela Lackner,Frédéric Lamoth,Fanny Lanternier,Cornelia Lass-Floerl,Dong-Gun Lee,Thomas Lehrnbecher,Badre E. Lmimouni,Mihai Mares,Georg Maschmeyer,Jacques F. Meis,Joseph Meletiadis,Joseph Meletiadis,C. Orla Morrissey,Marcio Nucci,Rita O. Oladele,Livio Pagano,Alessandro C. Pasqualotto,Atul Patel,Zdenek Racil,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Seyedmojtaba Seyedmousavi,Seyedmojtaba Seyedmousavi,Neeraj Sidharthan,Nina Singh,Janos Sinko,Anna Skiada,Monica A. Slavin,Monica A. Slavin,Rajeev Soman,Brad Spellberg,William J. Steinbach,Ban Hock Tan,Andrew J. Ullmann,Joerg J. Vehreschild,Maria J G T Vehreschild,Thomas J. Walsh,P. Lewis White,Nathan P. Wiederhold,Theoklis E. Zaoutis,Arunaloke Chakrabarti +79 more
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Journal ArticleDOI
Zygomycosis in a Tertiary-Care Cancer Center in the Era of Aspergillus-Active Antifungal Therapy: A Case-Control Observational Study of 27 Recent Cases
Dimitrios P. Kontoyiannis,Michail S. Lionakis,Russell E. Lewis,Russell E. Lewis,Georgios Chamilos,Mimi Healy,Cheryl Perego,Amar Safdar,Hagop M. Kantarjian,Richard E. Champlin,Thomas J. Walsh,Issam I Raad +11 more
TL;DR: Zygomycosis should be considered in immunosuppressed patients who develop sinusitis while receiving VRC prophylaxis, especially those with diabetes and malnutrition.
Journal ArticleDOI
Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis
TL;DR: Delayed amphotericin B-based therapy resulted in a 2-fold increase in mortality rate at 12 weeks after diagnosis, compared with early treatment, and the pursuit of aggressive diagnostic strategies and prompt initiation of antifungal agents with activity against Zygomycetes should be considered for patients with hematological malignancy who are at an increased risk for zygomyCosis.
Journal ArticleDOI
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
Georgios Chamilos,Mario A. Luna,Russell E. Lewis,Russell E. Lewis,Gerald P. Bodey,Roy F. Chemaly,Jeffrey J. Tarrand,Amar Safdar,Issam I Raad,Dimitrios P. Kontoyiannis +9 more
TL;DR: Among patients with invasive pulmonary aspergillosis, those with graft-versus-host disease had a histopathological pattern distinct from those with neutropenia, and the prevalence of all other IFI remained relatively constant.